Drugs / HyaRegen NCH
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04023383 | Jan 2017 → Jan 2019 | endometriosis | Bakirkoy Dr. Dr. Sadi Konuk Research and Training Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HyaRegen NCH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04023383 ↗ |
| Known as | NCH | “a New cross-linked hyaluronan (NCH) gel, that has higher viscosity compared to natural hyaluronan has been developed by BioRegen Biomedical (Changzhou, Jiangsu, China).” NCT04023383 ↗ |
| Modality | Other / unclassified | “New cross-linked hyaluronan (NCH) gel” NCT04023383 ↗ |
| Route | Other | “instilled into the peritoneal cavity” NCT04023383 ↗ |